These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 34244479

  • 1. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
    Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G, Liu Y, Yao Y, Chen X, Ma W, Zhang Z, Yuan Y.
    Cell Death Dis; 2021 Jul 09; 12(7):691. PubMed ID: 34244479
    [Abstract] [Full Text] [Related]

  • 2. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul 09; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 3. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y.
    Biomed Pharmacother; 2019 Jun 09; 114():108864. PubMed ID: 30981107
    [Abstract] [Full Text] [Related]

  • 4. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma.
    Zhang X, Wang W, Mo S, Sun X.
    Dig Dis Sci; 2024 Jun 09; 69(6):2096-2108. PubMed ID: 38653946
    [Abstract] [Full Text] [Related]

  • 5. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
    Zhou Y, Huang Y, Dai T, Hua Z, Xu J, Lin Y, Han L, Yue X, Ho L, Lu J, Ai X.
    Biomed Pharmacother; 2021 Jan 09; 133():111030. PubMed ID: 33378944
    [Abstract] [Full Text] [Related]

  • 6. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.
    Liu X, Gao X, Yang Y, Yang D, Guo Q, Li L, Liu S, Cong W, Lu S, Hou L, Wang B, Li N.
    Apoptosis; 2024 Aug 09; 29(7-8):1161-1184. PubMed ID: 38743191
    [Abstract] [Full Text] [Related]

  • 7. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B.
    Aging (Albany NY); 2020 Nov 16; 12(22):22975-23003. PubMed ID: 33203790
    [Abstract] [Full Text] [Related]

  • 8. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
    Li T, Dong ZR, Guo ZY, Wang CH, Zhi XT, Zhou JW, Li DK, Chen ZT, Chen ZQ, Hu SY.
    Liver Int; 2015 Apr 16; 35(4):1416-29. PubMed ID: 25066210
    [Abstract] [Full Text] [Related]

  • 9. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo.
    Yao S, Ye J, Yin M, Yu R.
    Cancer Lett; 2020 Jul 28; 483():87-97. PubMed ID: 32268165
    [Abstract] [Full Text] [Related]

  • 10. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
    Liu C, Peng X, Li Y, Liu S, Hou R, Zhang Y, Zuo S, Liu Z, Luo R, Li L, Fang W.
    Biomed Pharmacother; 2020 Mar 28; 123():109780. PubMed ID: 31901550
    [Abstract] [Full Text] [Related]

  • 11. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM.
    Gastroenterology; 2016 Dec 28; 151(6):1192-1205. PubMed ID: 27614046
    [Abstract] [Full Text] [Related]

  • 12. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
    Song Z, Liu T, Chen J, Ge C, Zhao F, Zhu M, Chen T, Cui Y, Tian H, Yao M, Li J, Li H.
    Cancer Lett; 2019 Sep 28; 460():96-107. PubMed ID: 31247273
    [Abstract] [Full Text] [Related]

  • 13. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 14. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H, Xu H, Ma F, Zhan M, Yang X, Hua S, Li W, Li Y, Lu L.
    Cell Death Dis; 2020 Apr 08; 11(4):225. PubMed ID: 32269215
    [Abstract] [Full Text] [Related]

  • 15. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M, Wang Z, Zhi X, Ding W, Xiong J, Tao T, Yang Y, Zhang H, Zi X, Zhou W, Huang G.
    Biomed Pharmacother; 2020 Sep 08; 129():110315. PubMed ID: 32554246
    [Abstract] [Full Text] [Related]

  • 16. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 Sep 08; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 17. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G, Shi Z, Shangguan C, Zhang J, Yuan Y, Chen L, Liu W, Li B, Meng S, Xiong W, Mi J.
    Theranostics; 2021 Sep 08; 11(12):6006-6018. PubMed ID: 33897895
    [Abstract] [Full Text] [Related]

  • 18. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L, Zhan Y, Wu Z, Lin M, Jin X, Jiang L, Qiu Y.
    Biomed Pharmacother; 2020 May 08; 125():110033. PubMed ID: 32187962
    [Abstract] [Full Text] [Related]

  • 19. WDR4 promotes HCC pathogenesis through N7-methylguanosine by regulating and interacting with METTL1.
    Dong R, Wang C, Tang B, Cheng Y, Peng X, Yang X, Ni B, Li J.
    Cell Signal; 2024 Jun 08; 118():111145. PubMed ID: 38493882
    [Abstract] [Full Text] [Related]

  • 20. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.
    Huang M, Long J, Yao Z, Zhao Y, Zhao Y, Liao J, Lei K, Xiao H, Dai Z, Peng S, Lin S, Xu L, Kuang M.
    Cancer Res; 2023 Jan 04; 83(1):89-102. PubMed ID: 36102722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.